⏳ Fetching live dividend data...
Home › Calculator › TBET Dividend Calculator 2026
Tibet Pharmaceuticals, Inc. · OTC
Price: $0.00 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in TBET → $55615527626940256.00M in 10 years · $377,192,933,882,270,060,000.00/month
Tibet Pharmaceuticals, Inc. operates as a specialized pharmaceutical company, primarily focused on the research, development, manufacturing, marketing, and distribution of traditional Tibetan medicines. The company conducts its core activities through its operational subsidiary, Yunnan Shangri-La Tibetan Pharmaceutical Group Limited (YSTP), which develops products within China to support the health of human respiratory, digestive, urinary, and reproductive systems. Among its currently commercialized products are: 25 Ingredients Mandrake Pill: Used for menstrual regulation and to address conditions like endometritis, pelvic inflammations, and anemia in women. 15 Ingredients Gentiana Pill: Prescribed for respiratory ailments including bronchitis, emphysema, asthma, and hoarseness. 28 Ingredients Pinang Pill: Aims to alleviate cold waist and hip pain, pus hematuria, and testicular swelling. 18 Ingredients Chebulic (Myrobalan) Frusemide Pill: Designed to treat various kidney issues, lower back and kidney pain, frequent or turbid urination, diabetes, and spermatorrhea. Pomegranate Nichirin Pill: Helps manage indigestion, back and leg pain, frequent urination, foot edema, impotence, and nocturnal emissions. The company also maintains an active development pipeline. The Xuezang Guben pill is being developed for neurasthenia, insomnia, frequent urination, nocturnal emission, and menopausal symptoms. Shengke I is currently in Phase III clinical testing for type II diabetes, while Shengke II is in Phase II trials, exploring its potential for impotence, premature ejaculation, prostate disease, and memory loss. The Jiuzan pill, also a Phase II candidate, targets chronic gastroenteritis and peptic ulcers. Additionally, Antai pill is a pre-clinical stage product under investigation for hepatitis B. Tibet Pharmaceuticals further plans to commercialize Wupeng Pill, intended for a range of conditions including echinococcosis, pandora tingling disease, diphtheria, anthrax, yellow water disease, and leprosy. Incorporated in 2009, the company was initially known as Shangri-La Tibetan Pharmaceuticals, Inc., before officially changing its name to Tibet Pharmaceuticals Inc. in July 2010. Its headquarters are located in Wanchai, Hong Kong.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open TBET position with:
Real after-tax yield depends on where you live and how you hold TBET.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2000000.00% | 1999997.20% | $200,000,000 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 1700000.00% | 1699997.20% | $170,000,000 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 1600000.00% | 1599997.20% | $160,000,000 / yr |
| 🇬🇧 UK ISA | 0% | 2000000.00% | 1999997.20% | $200,000,000 / yr |
| 🇬🇧 UK Taxable | 8.75% | 1825000.00% | 1824997.20% | $182,500,000 / yr |
| 🇨🇦 TFSA | 0% | 2000000.00% | 1999997.20% | $200,000,000 / yr |
| 🇨🇦 CA Taxable | 25% | 1500000.00% | 1499997.20% | $150,000,000 / yr |
| 🇦🇺 Super (pension) | 15% | 1700000.00% | 1699997.20% | $170,000,000 / yr |
| 🇦🇺 AU Taxable | 30% | 1400000.00% | 1399997.20% | $140,000,000 / yr |
| 🇩🇪 DE Taxable | 26.375% | 1472500.00% | 1472497.20% | $147,250,000 / yr |
| 🇫🇷 FR Taxable | 30% | 1400000.00% | 1399997.20% | $140,000,000 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
TBET pays quarterly — 4 times per year. Next ex-div: TBD.
How TBET compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for TBET sourced from FMP /financial-growth endpoint — real data, not estimates.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the TBET dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Tibet Pharmaceuticals, Inc. (TBET) is currently trading at $0.00, trading near its 52-week high. The current dividend yield is 2000000.00% based on an annual payout of $2.00 per share.
Tibet Pharmaceuticals, Inc. (TBET) is a healthcare stock currently trading at $0.00 with a dividend yield of 2000000.00%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings. Over the past 5 years, TBET has grown its dividend at a compound annual rate of 41.7%.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever